Compare Divis Laboratories with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUN PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUN PHARMA DIVIS LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 61.3 29.4 208.9% View Chart
P/BV x 14.1 4.0 356.1% View Chart
Dividend Yield % 0.4 1.0 41.4%  

Financials

 DIVIS LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-21
SUN PHARMA
Mar-21
DIVIS LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,913654 598.6%   
Low Rs1,824339 538.7%   
Sales per share (Unadj.) Rs262.5139.6 188.0%  
Earnings per share (Unadj.) Rs74.79.5 785.0%  
Cash flow per share (Unadj.) Rs84.418.2 463.8%  
Dividends per share (Unadj.) Rs20.007.50 266.7%  
Avg Dividend yield %0.71.5 46.1%  
Book value per share (Unadj.) Rs350.1193.6 180.8%  
Shares outstanding (eoy) m265.472,399.34 11.1%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x10.93.6 307.5%   
Avg P/E ratio x38.452.1 73.7%  
P/CF ratio (eoy) x34.027.3 124.7%  
Price / Book Value ratio x8.22.6 319.8%  
Dividend payout %26.878.8 34.0%   
Avg Mkt Cap Rs m761,5171,190,430 64.0%   
No. of employees `000NANA-   
Total wages/salary Rs m8,25868,622 12.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m69,694334,981 20.8%  
Other income Rs m6278,592 7.3%   
Total revenues Rs m70,321343,573 20.5%   
Gross profit Rs m28,61141,616 68.7%  
Depreciation Rs m2,55620,800 12.3%   
Interest Rs m211,414 1.5%   
Profit before tax Rs m26,66027,994 95.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,8185,147 132.5%   
Profit after tax Rs m19,84322,847 86.9%  
Gross profit margin %41.112.4 330.4%  
Effective tax rate %25.618.4 139.1%   
Net profit margin %28.56.8 417.5%  
BALANCE SHEET DATA
Current assets Rs m67,906304,421 22.3%   
Current liabilities Rs m17,284161,456 10.7%   
Net working cap to sales %72.642.7 170.2%  
Current ratio x3.91.9 208.4%  
Inventory Days Days10149 6.4%  
Debtors Days Days87899 889.3%  
Net fixed assets Rs m45,963336,682 13.7%   
Share capital Rs m5312,399 22.1%   
"Free" reserves Rs m92,415462,229 20.0%   
Net worth Rs m92,946464,628 20.0%   
Long term debt Rs m08,981 0.0%   
Total assets Rs m113,869641,103 17.8%  
Interest coverage x1,270.520.8 6,110.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 117.1%   
Return on assets %17.43.8 461.0%  
Return on equity %21.34.9 434.2%  
Return on capital %28.76.2 462.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m084,493 0.0%   
Fx outflow Rs m030,334 0.0%   
Net fx Rs m054,159 0.0%   
CASH FLOW
From Operations Rs m19,46961,704 31.6%  
From Investments Rs m7515,362 14.0%  
From Financial Activity Rs m-349-59,805 0.6%  
Net Cashflow Rs m19,8725,964 333.2%  

Share Holding

Indian Promoters % 52.0 54.5 95.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.1 33.8 109.6%  
FIIs % 20.7 12.1 171.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.1 45.5 105.6%  
Shareholders   223,403 675,908 33.1%  
Pledged promoter(s) holding % 0.0 6.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   FERMENTA BIOTECH  CHANDRA BHAGAT PHARMA  ZANDU REALTY  GRANULES INDIA  BAL PHARMA  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Slumped 1,688 Points Today(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended deep in the red.

Related Views on News

SUN PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 22, 2021 | Updated on Oct 22, 2021

Here's an analysis of the annual report of SUN PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

DIVIS LABORATORIES 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of DIVIS LABORATORIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY22); Net Profit Up 13.2% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, DIVIS LABORATORIES has posted a net profit of Rs 6 bn (up 13.2% YoY). Sales on the other hand came in at Rs 20 bn (up 13.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY21); Net Profit Up 29.3% (Quarterly Result Update)

Jun 28, 2021 | Updated on Jun 28, 2021

For the quarter ended March 2021, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 29.3% YoY). Sales on the other hand came in at Rs 18 bn (up 28.7% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

How to Hit Rs 100 Crore Wealth in Your Lifetime(Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 26, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS